NICE nod for AstraZeneca drug in HFrEF

7 January 2021

The UK National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Document (FAD) recommending Forxiga (dapagliflozin) for symptomatic chronic heart failure (HF) with reduced ejection fraction (HFrEF) in adults, as an add-on to optimised standard care.

NICE, the cost-effectiveness watchdog for England and Wales, recommends that treatment with the AstraZeneca (LSE: AZN) drug is started on the advice of a heart failure specialist, and that monitoring should be done by the most appropriate healthcare professional.

Forxiga, which is also branded as Farxiga, is in a class of drugs called SGLT2 inhibitors, and is the first medicine of this kind to be licensed and recommended for use in HF.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK